Literature DB >> 9408477

Alternate endpoints for seizure measurement.

J A Cramer1.   

Abstract

The type of seizure measurement selected should be tailored to the needs of the clinical trial. These needs change as the development of the investigational agent moves along. Protocol designers who look toward nontraditional outcome measures might acquire valuable data that could be used to differentiate their drug from other new treatments. Most importantly, as clinical trials evolve into effectiveness studies, clinicians are provided with useful data on which to base selection of a drug of first choice to treat each type of seizure disorder.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9408477

Source DB:  PubMed          Journal:  Adv Neurol        ISSN: 0091-3952


  1 in total

Review 1.  Seizure control as a new metric in assessing efficacy of tumor treatment in low-grade glioma trials.

Authors:  Edward K Avila; Marc Chamberlain; David Schiff; Jaap C Reijneveld; Terri S Armstrong; Roberta Ruda; Patrick Y Wen; Michael Weller; Johan A F Koekkoek; Sandeep Mittal; Yoshiki Arakawa; Ali Choucair; Jorge Gonzalez-Martinez; David R MacDonald; Ryo Nishikawa; Aashit Shah; Charles J Vecht; Paula Warren; Martin J van den Bent; Lisa M DeAngelis
Journal:  Neuro Oncol       Date:  2016-09-20       Impact factor: 12.300

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.